Clinical trial Recruiting at 1 site Interventional Ages 20 to 45 Women only

Doxycycline with or without progestin for chronic endometritis in women with recurrent reproductive failure

Official title: Clinical Efficacy and Pregnancy Outcomes of Doxycycline Combined With Medroxyprogesterone Acetate Therapy for Chronic Endometritis(CE) in Patients With Recurrent Reproductive Failure(RRF): A Prospective Randomized Controlled Trial

Run by Lanzhou University Second Hospital · NCT07488949 · Data updated 2026-11-12

This trial tests whether adding the progestin medroxyprogesterone acetate to doxycycline improves pregnancy outcomes for women with chronic endometritis and recurrent reproductive failure.

More Chronic Endometritis trials

Quick facts

Study typeInterventional
Ages20 Years to 45 Years
SexWomen only
Enrollment1000 (estimated)
SponsorLanzhou University Second Hospital
Academic / other
Locations1 site (Lanzhou, Gansu)
StatusRecruiting
StartedApril 9, 2024
Main results expectedDecember 31, 2030
Study endsDecember 31, 2031
Registry record updatedMarch 23, 2026
Trial IDNCT07488949 on ClinicalTrials.gov

Is this trial a fit for you?

Likely a good fit

Women age 20–45 who have CD138-confirmed chronic endometritis, a diagnosis of recurrent reproductive failure, plan to conceive within 12 months, and have no contraindication to hysteroscopy or the study medications.

Probably not a fit

Women whose infertility is due to other causes such as uterine structural disease, active genital infection, male factor infertility, contraindications to the medications, pregnancy or lactation are unlikely to benefit from this protocol.

A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.

What this trial studies

This randomized controlled trial assigns women aged 20–45 with CD138-confirmed chronic endometritis and recurrent reproductive failure to receive either doxycycline plus medroxyprogesterone acetate or doxycycline plus placebo. Participants must be planning to conceive within 12 months and will undergo hysteroscopy and endometrial biopsy at baseline. The study follows participants for reproductive outcomes including pregnancy, ongoing pregnancy, spontaneous miscarriage, and live birth. Safety and tolerability of the treatment regimens will also be monitored.

Why it matters

Potential benefit: If successful, adding MPA to doxycycline could increase pregnancy and live birth rates for women with chronic endometritis and recurrent reproductive failure.

How similar studies have gone: Antibiotic treatment for chronic endometritis has shown some success in improving reproductive outcomes, but combining doxycycline with a progestin like MPA is relatively novel and not yet well established.

Who can join: the full rules

Show full inclusion / exclusion criteria
Inclusion Criteria:

* women aged 20-45 years;
* plans to conceive within 12 months;
* chronic endometritis(CE) confirmed by endometrial CD138 immunohistochemistry (IHC);
* a diagnosis of recurrent reproductive failure(RRF);
* willingness to undergo hysteroscopy and endometrial biopsy;
* no contraindications to the study medications.

Exclusion Criteria:

* acute genital tract infection, gynecologic malignancy, endometrial hyperplasia, or uterine fibroids;
* pregnancy or lactation;
* contraindications to hysteroscopy or anesthesia;
* use of antibiotics, glucocorticoids, estrogens, or progestins within 3 months before trial initiation;
* allergy to doxycycline or medroxyprogesterone acetate(MPA);
* abnormal semen parameters in the male partner.

Where it's running

  • Lanzhou University Second Hospital
    Lanzhou, Gansu, China
    Recruiting

Study contacts

Similar studies

Other studies for the same condition or treatment. Recruiting studies are listed first.

How to take part

  1. Review the eligibility criteria above with your treating physician.
  2. Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
  3. Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.
Last reviewed 2026-11-14 by the Find a Trial editorial team. Information on this page is for educational purposes and is not medical advice. Always consult qualified healthcare professionals about clinical trial participation.